Insomnia is a classification of sleep disorders in which a person has trouble falling asleep, staying asleep or waking up too early. These disorders may also be defined by an overall poor quality of sleep. Insomnia is the most commonly reported sleep disorder. About 30 percent of adults have symptoms of insomnia. On average, most adults need seven to eight hours of sleep each night to feel alert and well-rested.
Xenazine (tetrabenazine) for the treatment of chorea i.e. jerky, involuntary movements in people with Huntington?s disease. – The U.S. Food and Drug Administration has approved Xenazine (tetrabenazine) for the treatment of chorea in people with Huntington’s disease. Chorea is the jerky, involuntary movement that occurs in people with this disease.
New Study in the Journal SLEEP Finds that a Short-Term Dose of Zolpidem is an Effective Treatment for Insomnia. – Zolpidem extended-release 12.5 mg, taken three to seven nights per week for up to six months, provided sustained and significant improvements in sleep onset and maintenance, and also improved next-day concentration and morning sleepiness in people with insomnia.
FDA is warning consumers not to use Swad brand sindoor because the product contains high levels of lead, leading to lead toxicity or lead poisoning.
– The U.S. Food and Drug Administration is warning consumers not to use 3.5 oz. packages of Swad brand sindoor, an orange or red powder used in some traditional South Asian Pacific ceremonies that is applied to the face or scalp, imported by Raja Foods LLC of Skokie, Illinois because the product contains high levels of lead. Although the product was not intended to be sold for food use, its labeling is confusing and implies that it may be used as food.
